ACON Laboratories, Inc. company was founded in 1995 and is based in San Diego, California. ACON Laboratories has a contracted manufacturing facility located in Hangzhou, China. ACON Laboratories, Inc. engages in the custom product design and contract manufacturing of diagnostic healthcare products. It offers rapid test products for fertility, infectious diseases, and drugs of abuse, as well as provides tumor markers, cardiac markers, lateral flow immunoassay products, blood glucose monitoring systems, and urinalysis products. The company also provides urinalysis reagent strips, breath alcohol detectors, antibodies test kits, urine analyzers, antibody enzyme immunoassay (EIA) test kits, hepatitis B virus EIA test kits, hepatitis C virus antibody EIA test kits, syphilis antibody EIA test kits, antigen test devices, gonorrhea and Chlamydia test strips, gonorrhea test strips, and tuberculosis test devices. In addition, it offers diagnostic rapid test products, which are used to detect pregnancy, ovulation, menopause, HCV, HIV, helicobacter pyloris, malaria, and dengue. The company supplies its products to hospitals, clinical laboratories, blood banks, and consumer outlets. ACON Laboratories sells its products through independent medical distributors in Asia, the Middle East, Africa, the Russian Federation, and Latin America.

MediGene develops drugs that save lives or just make life easier. Spun off from the Munich Gene Center in 1994, MediGene focuses its R&D efforts on therapies that battle various forms of cancer and autoimmune conditions. It also has several drugs on the market, many of them sold through partnerships with other drug firms. The company's Eligard treatment for prostate cancer is sold in Europe by Astellas Pharma, and its Veregen ointment for genital warts is on the US market (Bradley Pharmaceuticals (now part of Nycomed US) sells the drug). In 2008 MediGene won approval from European regulatory authorities for Oracea, a treatment for rosacea; it sold European marketing rights for the drug to Galderma Laboratories.

VaxGen, Inc. company was founded in 1995 and is based in South San Francisco, California. VaxGen, Inc., (VaxGen) is a biopharmaceutical company. VaxGen is focused on the development, manufacture and commercialization of biologic products for the treatment of human disease. The Company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. The Company has ended all product development activities and sold or otherwise terminated its drug development programs. On March 28, 2008, the Company entered into a Termination of Merger Agreement, Acknowledgment and Amendment to Loan Agreement and Secured Promissory Note, or Termination Agreement and Amendment, terminating immediately the Merger Agreement and amending the terms of VaxGen’s bridge loan to Raven.

Tekmira Pharmaceuticals is giving diseases the silent treatment. The biopharmaceutical company is attempting to develop therapies that inhibit or "silence" certain disease-causing genes through ribonucleic acid interference (RNAi), a mechanism that disrupts the production of proteins that can lead to cancer, metabolic, and infectious diseases. Tekmira's lead candidates are being developed to treat tumors and high cholesterol. It also partners with other pharmaceutical companies, such as Alnylam Pharmaceuticals and Roche, to advance additional RNAi products using Tekmira's stable nucleic acid-lipid particles (SNALP) RNAi drug delivery technology.

BioVex Group has developed a virus-containing vaccine which works to prevent and combat certain types of cancer and chronic infectious diseases. The company's lead product, OncoVEX, makes use of an altered virus to attack solid tumor cells but leave healthy cells intact. OncoVEX has shown promise in treating metastatic melanoma and the company has plans to vex other cancers such as pancreatic and colo-rectal cancers. After a brief stint as a publicly-traded company, in 2007 BioVex was taken private by a group of investors led by health science-oriented Triathlon Medical Ventures.

Tridelta specialises in the development, manufacturing and marketing of diagnostic products for the animal health care industry. The company has commercialised five technologies to date with its "PHASE" range of Acute Phase Protein Assays, which are indicators of the presence of an inflammatory reaction, detected in the blood before the animal shows any physical signs of ill health. Species of specific interest include: cattle, horses, sheep, cats, dogs, pigs and rodents.

Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate dutogliptin is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and certain types of cancer. The biotechnology firm's drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. The company is owned by a number of private investors.

Richter Gedeon was founded by Gedeon Richter in 1901. Richter Gedeon is less interested with Earth's tremors than it is with rumblings caused by human pain and ailments. Hungary's largest producer of pharmaceuticals, the company makes female hormones, ACE inhibitors, anti-anxiety drugs and OTC pain relievers, anti-inflammatories, and vitamin supplements. It specializes in gynecological, cardiovascular, and central nervous system treatments. Brands include Normodipine, Diroton, Panangin, Cavinton, and Mydeton. Richter has a presence in 30 countries; its products are distributed worldwide through its subsidiaries.

Proteome Sciences plc is a United Kingdom-based company. The Company is principally engaged in biomarker research and development primarily in the field of applied proteomics, using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Through its ProteoSHOP toolkit, Proteome Sciences provides proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and gel-free protein sequence tag technologies (PST, qPST& TMT), to pharma, biotechnology and diagnostic companies. The Company has research facilities in London, the United Kingdom and Frankfurt, Germany. Its subsidiaries include Proteome Sciences R&D Verwaltungs GmbH, Proteome Sciences R&D GmbH & Co. KG, Xzillion GmbH & Co. KG, Proteome Sciences, Inc., Veri-Q Inc., Phenomics Limited and Electrophoretics Limited.

Salix Pharmaceuticals, Ltd. company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. As of December 31, 2008, the Company’s products were XIFAXAN (rifaximin) Tablets 200 milligram; MOVIPREP; OSMOPREP, VISICOL Tablets, AZASAN Azathioprine Tablets, USP, 75/100 milligram; ANUSOL-HC 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC 25 milligram Suppository (Hydrocortisone Acetate); PROCTOCORT Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 milligram; PEPCID (famotidine) for Oral Suspension; Oral Suspension DIURIL (Chlorothiazide); APRISO (mesalamine) extended-release capsules 0.375 grams, and COLAZAL (balsalazide disodium) Capsules 750 milligram.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.